426 related articles for article (PubMed ID: 33996712)
1. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
Front Public Health; 2021; 9():628744. PubMed ID: 33996712
[No Abstract] [Full Text] [Related]
2. Access to cardiovascular medicines in low- and middle-income countries: a mini review.
Harrison MA; Marfo AFA; Annan A; Ankrah DNA
Glob Health Res Policy; 2023 May; 8(1):17. PubMed ID: 37221559
[TBL] [Abstract][Full Text] [Related]
3. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Babar ZU; Lessing C; Mace C; Bissell K
Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
[TBL] [Abstract][Full Text] [Related]
4. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
[TBL] [Abstract][Full Text] [Related]
5. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
[TBL] [Abstract][Full Text] [Related]
6. A systematic scoping review of medicine availability and affordability in Africa.
Lane J; Nakambale H; Kadakia A; Dambisya Y; Stergachis A; Odoch WD
BMC Health Serv Res; 2024 Jan; 24(1):91. PubMed ID: 38233851
[TBL] [Abstract][Full Text] [Related]
7. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
8. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
9. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review.
Stolbrink M; Thomson H; Hadfield RM; Ozoh OB; Nantanda R; Jayasooriya S; Allwood B; Halpin DMG; Salvi S; de Oca MM; Mortimer K; Rylance S
Lancet Glob Health; 2022 Oct; 10(10):e1423-e1442. PubMed ID: 36113528
[TBL] [Abstract][Full Text] [Related]
10. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Ewen M; Dreser A; Bautista-Arredondo S; Soria-Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
BMC Health Serv Res; 2020 May; 20(1):424. PubMed ID: 32410676
[TBL] [Abstract][Full Text] [Related]
11. Medicine Prices, Availability, and Affordability in Private Health Facilities in Low-Income Settlements in Nairobi County, Kenya.
Ongarora D; Karumbi J; Minnaard W; Abuga K; Okungu V; Kibwage I
Pharmacy (Basel); 2019 Apr; 7(2):. PubMed ID: 31022841
[TBL] [Abstract][Full Text] [Related]
12. The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries.
Babar ZU; Ramzan S; El-Dahiyat F; Tachmazidis I; Adebisi A; Hasan SS
Front Pharmacol; 2019; 10():1375. PubMed ID: 31824316
[No Abstract] [Full Text] [Related]
13. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
14. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
[TBL] [Abstract][Full Text] [Related]
16. Accessibility of essential anticancer medicines for children in the Sichuan Province of China.
Chen Z; Li S; Zou K; Li H; Zeng L; Lu X; Jia ZJ; Cheng G; Zhang L
Front Public Health; 2022; 10():980969. PubMed ID: 36408013
[TBL] [Abstract][Full Text] [Related]
17. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
Babar ZU
Res Social Adm Pharm; 2024 Jun; ():. PubMed ID: 38908991
[TBL] [Abstract][Full Text] [Related]
18. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
Ewen M; Zweekhorst M; Regeer B; Laing R
PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
[TBL] [Abstract][Full Text] [Related]
19. Product patents and access to innovative medicines.
Dai R; Watal J
Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
[TBL] [Abstract][Full Text] [Related]
20. Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.
Babar ZU
J Pharm Policy Pract; 2022 Feb; 15(1):9. PubMed ID: 35209945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
